Publications searcher

The science produced by our scientists is very important. In 2024, 1,501 papers were published in scientific journals with an average impact factor of over 7.13 points.

First Nationwide Molecular Screening Program in Spain for Patients With Advanced Breast Cancer: Results From the AGATA SOLTI-1301 Study.

PMID: 34804931
Journal: Frontiers in Oncology
Year: 2021
Reference: Front Oncol. 2021 Nov 4;11:744112. doi: 10.3389/fonc.2021.744112. eCollection 2021.
Impact factor: 6.244
Publication type: Paper in international publication
Authors: Burgues, Octavio, Pernas, Sonia, Villagrasa, Patricia, Vivancos, Ana, Scaltriti, Maurizio, Rodon, Jordi, Pare, Laia, Duenas, Marta, Vidal, Maria, Cejalvo, Juan Miguel et al.
DOI: 10.3389/fonc.2021.744112

First Nationwide Molecular Screening Program in Spain for Patients With Advanced Breast Cancer: Results From the AGATA SOLTI-1301 Study.

PMID: 34804931
Journal: Frontiers in Oncology
Year: 2021
Reference: Front Oncol. 2021 Nov 4;11:744112. doi: 10.3389/fonc.2021.744112. eCollection 2021.
Impact factor:
Publication type: Paper in international publication
Authors: Burgues, Octavio; Canes, Jordi; Cejalvo, Juan Miguel; Ciruelos, Eva; Dorca, Joan; Duenas, Marta; Llommbard-Cussac, Antonio; Montano, Alvaro; Nuciforo, Paolo; Oliveira, Mafalda et al.
DOI: 10.3389/fonc.2021.744112

First-In-Human Phase I Study of a Next-Generation, Oral, TGFbeta Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer.

PMID: 34548321
Journal: CLINICAL CANCER RESEARCH
Year: 2021
Reference: Clin Cancer Res. 2021 Dec 15;27(24):6666-6676. doi: 10.1158/1078-0432.CCR-21-1504. Epub 2021 Sep 21.
Impact factor: 12.531
Publication type: Paper in international publication
Authors: Simonelli, Matteo, Cosman, Rasha, van der Westhuizen, Andre, Atkinson, Victoria, Carpentier, Antoine F, Lohr, Mario, Redman, Rebecca, Mason, Warren, Cervantes, Andres, Le Rhun, Emilie et al.
DOI: 10.1158/1078-0432.CCR-21-1504

First-In-Human Phase I Study of a Next-Generation, Oral, TGFbeta Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer.

PMID: 34548321
Journal: CLINICAL CANCER RESEARCH
Year: 2021
Reference: Clin Cancer Res. 2021 Dec 15;27(24):6666-6676. doi: 10.1158/1078-0432.CCR-21-1504. Epub 2021 Sep 21.
Impact factor:
Publication type: Paper in international publication
Authors: Atkinson, Victoria; Avsar, Emin; Baldini, Capucine; Callies, Sophie; Carpentier, Antoine F; Cervantes, Andres; Cosman, Rasha; Estrem, Shawn T; Gandhi, Leena; Kondo, Shunsuke et al.
DOI: 10.1158/1078-0432.CCR-21-1504

First-in-Human Phase I Study of MP0250, a First-in-Class DARPin Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid Tumors.

PMID: 33301375
Journal: JOURNAL OF CLINICAL ONCOLOGY
Year: 2021
Reference: J Clin Oncol. 2021 Jan 10;39(2):145-154. doi: 10.1200/JCO.20.00596. Epub 2020 Dec 10.
Impact factor: 44.544
Publication type: Paper in international publication
Authors: Stumpp, Michael T, Harstrick, Andreas, Azaro, Analia, Fischer, Stefanie, Omlin, Aurelius, Leupin, Nicolas, Dawson, Keith M, Fiedler, Ulrike, Zitt, Christof, Baird, Richard D et al.
DOI: 10.1200/JCO.20.00596

First-in-Human Phase I Study of MP0250, a First-in-Class DARPin Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid Tumors.

PMID: 33301375
Journal: JOURNAL OF CLINICAL ONCOLOGY
Year: 2021
Reference: J Clin Oncol. 2021 Jan 10;39(2):145-154. doi: 10.1200/JCO.20.00596. Epub 2020 Dec 10.
Impact factor:
Publication type: Paper in international publication
Authors: Azaro, Analia; Baird, Richard D; Dawson, Keith M; Fiedler, Ulrike; Fischer, Stefanie; Harris, Adrian; Harstrick, Andreas; Leupin, Nicolas; Linossi, Constanza; Lord, Simon et al.
DOI: 10.1200/JCO.20.00596

First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas.

PMID: 34389618
Journal: Journal for ImmunoTherapy of Cancer
Year: 2021
Reference: J Immunother Cancer. 2021 Aug;9(8). pii: jitc-2021-002863. doi: 10.1136/jitc-2021-002863.
Impact factor: 13.751
Publication type: Paper in international publication
Authors: Piha-Paul, Sarina A, Geva, Ravit, Tan, Tira J, Lim, Darren Wt, Hierro, Cinta, Doi, Toshikiko, Rahma, Osama, Lesokhin, Alexander, Luke, Jason John, Otero, Javier et al.
DOI: 10.1136/jitc-2021-002863

First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas.

PMID: 34389618
Journal: Journal for ImmunoTherapy of Cancer
Year: 2021
Reference: J Immunother Cancer. 2021 Aug;9(8). pii: jitc-2021-002863. doi: 10.1136/jitc-2021-002863.
Impact factor:
Publication type: Paper in international publication
Authors: Bedard, Philippe L; Chen, Xinhui; Doi, Toshikiko; Geva, Ravit; Hierro, Cinta; Lesokhin, Alexander; Lim, Darren Wt; Luke, Jason John; Mataraza, Jennifer; Nardi, Lisa et al.
DOI: 10.1136/jitc-2021-002863

First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II study.

PMID: 33957442
Journal: EUROPEAN JOURNAL OF CANCER
Year: 2021
Reference: Eur J Cancer. 2021 Jul;151:14-24. doi: 10.1016/j.ejca.2021.03.028. Epub 2021 May 4.
Impact factor:
Publication type: Paper in international publication
Authors: Bekaii-Saab, Tanios; Belanger, Bruce; Boland, Patrick M; Dayyani, Farshid; Dean, Andrew; Macarulla, Teresa; Maxwell, Fiona; Mody, Kabir; Moore, Yan; Thiagalingam, Arunthathi et al.
DOI: 10.1016/j.ejca.2021.03.028

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.

PMID: 33476593
Journal: LANCET ONCOLOGY
Year: 2021
Reference: Lancet Oncol. 2021 Feb;22(2):198-211. doi: 10.1016/S1470-2045(20)30641-0. Epub 2021 Jan 18.
Impact factor: 41.316
Publication type: Paper in international publication
Authors: Oukessou, Abderrahim, Yan, Jinchun, Reck, Martin, Agrawal, Shruti, Meadows-Shropshire, Stephanie, Carbone, David P, John, Thomas, Paz-Ares, Luis, Ciuleanu, Tudor-Eliade, Cobo, Manuel et al.
DOI: 10.1016/S1470-2045(20)30641-0

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.

PMID: 33476593
Journal: LANCET ONCOLOGY
Year: 2021
Reference: Lancet Oncol. 2021 Feb;22(2):198-211. doi: 10.1016/S1470-2045(20)30641-0. Epub 2021 Jan 18.
Impact factor:
Publication type: Paper in international publication
Authors: Agrawal, Shruti; Alexandru, Aurelia; Bennouna, Jaafar; Carbone, David P; Ciuleanu, Tudor-Eliade; Cobo, Manuel; De Marchi, Pedro; Felip, Enriqueta; John, Thomas; Juan-Vidal, Oscar et al.
DOI: 10.1016/S1470-2045(20)30641-0

First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update.

PMID: 34607285
Journal: ESMO Open
Year: 2021
Reference: ESMO Open. 2021 Oct;6(5):100273. doi: 10.1016/j.esmoop.2021.100273. Epub 2021 Oct 1.
Impact factor: 6.54
Publication type: Paper in international publication
Authors: Tran, P, John, T, Zhang, X, Marimuthu, S, Memaj, A, Carbone, D P, Reck, M, Ciuleanu, T-E, Cobo, M, Schenker, M et al.
DOI: 10.1016/j.esmoop.2021.100273

First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update.

PMID: 34607285
Journal: ESMO Open
Year: 2021
Reference: ESMO Open. 2021 Oct;6(5):100273. doi: 10.1016/j.esmoop.2021.100273. Epub 2021 Oct 1.
Impact factor:
Publication type: Paper in international publication
Authors: Alexandru, A; Bennouna, J; Carbone, D P; Ciuleanu, T-E; Cobo, M; De Marchi, P; Felip, E; John, T; Juan-Vidal, O; Lingua, A et al.
DOI: 10.1016/j.esmoop.2021.100273

First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811.

PMID: 33167735
Journal: Future Oncology
Year: 2021
Reference: Future Oncol. 2021 Feb;17(5):491-501. doi: 10.2217/fon-2020-0737. Epub 2020 Nov 10.
Impact factor:
Publication type: Paper in international publication
Authors: Alsina, Maria; Bang, Yung-Jue; Bhagia, Pooja; Cao, Zhu Alexander; Chung, Hyun Cheol; Cutsem, Eric van; Janjigian, Yelena Y; Lu, Jia; Qin, Shu-Kui; S Fuchs, Charles et al.
DOI: 10.2217/fon-2020-0737

Fit-for-Discharge Criteria after Esophagectomy: An International Expert Delphi Consensus.

PMID: 32960264
Journal: DISEASES OF THE ESOPHAGUS
Year: 2021
Reference: Dis Esophagus. 2021 Jun 14;34(6). pii: 5909885. doi: 10.1093/dote/doaa101.
Impact factor: 3.429
Publication type: Paper in international publication
Authors: van Veer, H, Low, D E, Luyer, M, Markar, S R, Monig, S P, Moorthy, K, Morse, C R, Muller-Stich, B P, Nafteux, P, Nieponice, A et al.
DOI: 10.1093/dote/doaa101

Fit-for-Discharge Criteria after Esophagectomy: An International Expert Delphi Consensus.

PMID: 32960264
Journal: DISEASES OF THE ESOPHAGUS
Year: 2021
Reference: Dis Esophagus. 2021 Jun 14;34(6). pii: 5909885. doi: 10.1093/dote/doaa101.
Impact factor:
Publication type: Paper in international publication
Authors: Bonavina, L; Brown, W; Castro, S; Cheong, E; Darling, G E; Egberts, J; Ferri, L; Gisbertz, S S; Gockel, I; Grimminger, P P et al.
DOI: 10.1093/dote/doaa101

Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer.

PMID: 33449799
Journal: JOURNAL OF CLINICAL ONCOLOGY
Year: 2021
Reference: J Clin Oncol. 2021 Mar 1;39(7):723-733. doi: 10.1200/JCO.20.01605. Epub 2021 Jan 15.
Impact factor: 44.544
Publication type: Paper in international publication
Authors: Burgio, Marco Angelo, Borghaei, Hossein, Gettinger, Scott, Vokes, Everett E, Chow, Laura Q M, Marimuthu, Sathiya, Arrieta, Oscar, Frontera, Osvaldo Aren, Chiari, Rita, Butts, Charles et al.
DOI: 10.1200/JCO.20.01605

Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer.

PMID: 33449799
Journal: JOURNAL OF CLINICAL ONCOLOGY
Year: 2021
Reference: J Clin Oncol. 2021 Mar 1;39(7):723-733. doi: 10.1200/JCO.20.01605. Epub 2021 Jan 15.
Impact factor:
Publication type: Paper in international publication
Authors: Antonia, Scott; Arrieta, Oscar; Barlesi, Fabrice; Borghaei, Hossein; Brahmer, Julie; Burgio, Marco Angelo; Butts, Charles; Chiari, Rita; Chow, Laura Q M; Coudert, Bruno et al.
DOI: 10.1200/JCO.20.01605

Five-year prognosis after TIA or minor ischemic stroke in Asian and non-Asian countries.

PMID: 33046613
Journal: NEUROLOGY
Year: 2021
Reference: Neurology. 2021 Jan 5;96(1):e54-e66. doi: 10.1212/WNL.0000000000010995. Epub 2020 Oct 12.
Impact factor: 9.91
Publication type: Paper in international publication
Authors: Caplan, Louis R, Hoshino, Takao, Uchiyama, Shinichiro, Wong, Lawrence K S, Kitagawa, Kazuo, Charles, Hugo, Labreuche, Julien, Lavallee, Philippa C, Albers, Gregory W, Hennerici, Michael G et al.
DOI: 10.1212/WNL.0000000000010995

Five-year prognosis after TIA or minor ischemic stroke in Asian and non-Asian countries.

PMID: 33046613
Journal: NEUROLOGY
Year: 2021
Reference: Neurology. 2021 Jan 5;96(1):e54-e66. doi: 10.1212/WNL.0000000000010995. Epub 2020 Oct 12.
Impact factor:
Publication type: Paper in international publication
Authors: Albers, Gregory W; Amarenco, Pierre; Caplan, Louis R; Charles, Hugo; Donnan, Geoffrey A; Ferro, Jose M; Gabriel Steg, P; Hennerici, Michael G; Hoshino, Takao; Kitagawa, Kazuo et al.
DOI: 10.1212/WNL.0000000000010995

Fluid balance and outcome in critically ill patients with traumatic brain injury (CENTER-TBI and OzENTER-TBI): a prospective, multicentre, comparative effectiveness study.

PMID: 34302787
Journal: LANCET NEUROLOGY
Year: 2021
Reference: Lancet Neurol. 2021 Aug;20(8):627-638. doi: 10.1016/S1474-4422(21)00162-9.
Impact factor: 44.182
Publication type: Paper in international publication
Authors: Frisvold, Shirin, Wiegers, Eveline Janine Anna, Lingsma, Hester Floor, Huijben, Jilske Antonia, Cooper, David James, Citerio, Giuseppe, Furmanov, Alex, Verheyden, Jan, Misset, Benoit, Ledoux, Didier et al.
DOI: 10.1016/S1474-4422(21)00162-9

Fluid balance and outcome in critically ill patients with traumatic brain injury (CENTER-TBI and OzENTER-TBI): a prospective, multicentre, comparative effectiveness study.

PMID: 34302787
Journal: LANCET NEUROLOGY
Year: 2021
Reference: Lancet Neurol. 2021 Aug;20(8):627-638. doi: 10.1016/S1474-4422(21)00162-9.
Impact factor:
Publication type: Paper in international publication
Authors: Ackerlund, Cecilia; Adams, Hadie; Amrein, Krisztina; Andelic, Nada; Andreassen, Lasse; Anke, Audny; Antoni, Anna; Audibert, Gerard; Azouvi, Philippe; Azzolini, Maria Luisa et al.
DOI: 10.1016/S1474-4422(21)00162-9

Fluorescence-based bowel anastomosis perfusion evaluation: results from the IHU-IRCAD-EAES EURO-FIGS registry.

PMID: 33492508
Journal: SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES
Year: 2021
Reference: Surg Endosc. 2021 Dec;35(12):7142-7153. doi: 10.1007/s00464-020-08234-8. Epub 2021 Jan 25.
Impact factor: 4.584
Publication type: Paper in international publication
Authors: de Manzini, Nicolo, Spota, Andrea, Al-Taher, Mahdi, Felli, Eric, Morales Conde, Salvador, Dal Dosso, Ivano, Moretto, Gianluigi, Spinoglio, Giuseppe, Baiocchi, Gianluca, Vilallonga, Ramon et al.
DOI: 10.1007/s00464-020-08234-8

Fluorescence-based bowel anastomosis perfusion evaluation: results from the IHU-IRCAD-EAES EURO-FIGS registry.

PMID: 33492508
Journal: SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES
Year: 2021
Reference: Surg Endosc. 2021 Dec;35(12):7142-7153. doi: 10.1007/s00464-020-08234-8. Epub 2021 Jan 25.
Impact factor:
Publication type: Paper in international publication
Authors: Al-Taher, Mahdi; Anania, Gabriele; Baiocchi, Gianluca; Balla, Andrea; Bertani, Emilio; Bianchi, Giorgio; Boni, Luigi; Calabro, Marcello; Carus, Thomas; Casali, Lorenzo et al.
DOI: 10.1007/s00464-020-08234-8

Publications

Publications searcher

First Nationwide Molecular Screening Program in Spain for Patients With Advanced Breast Cancer: Results From the AGATA SOLTI-1301 Study.

First Nationwide Molecular Screening Program in Spain for Patients With Advanced Breast Cancer: Results From the AGATA SOLTI-1301 Study.

First-In-Human Phase I Study of a Next-Generation, Oral, TGFbeta Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer.

First-In-Human Phase I Study of a Next-Generation, Oral, TGFbeta Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer.

First-in-Human Phase I Study of MP0250, a First-in-Class DARPin Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid Tumors.

First-in-Human Phase I Study of MP0250, a First-in-Class DARPin Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid Tumors.

First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas.

First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas.

First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II study.

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.

First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update.

First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update.

First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811.

Fit-for-Discharge Criteria after Esophagectomy: An International Expert Delphi Consensus.

Fit-for-Discharge Criteria after Esophagectomy: An International Expert Delphi Consensus.

Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer.

Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer.

Five-year prognosis after TIA or minor ischemic stroke in Asian and non-Asian countries.

Five-year prognosis after TIA or minor ischemic stroke in Asian and non-Asian countries.

Fluid balance and outcome in critically ill patients with traumatic brain injury (CENTER-TBI and OzENTER-TBI): a prospective, multicentre, comparative effectiveness study.

Fluid balance and outcome in critically ill patients with traumatic brain injury (CENTER-TBI and OzENTER-TBI): a prospective, multicentre, comparative effectiveness study.

Fluorescence-based bowel anastomosis perfusion evaluation: results from the IHU-IRCAD-EAES EURO-FIGS registry.

Fluorescence-based bowel anastomosis perfusion evaluation: results from the IHU-IRCAD-EAES EURO-FIGS registry.

Patronage:

Collaborating:

Accreditations: